Dr. Andrea Apolo

is trying to answer that question, treating with atezolizumab, using ctDNA to treat those patients. The modern study here in the US is also asking that question, using ctDNA to decide whether you intensify the treatment or whether you do you really need the treatment, and really only treating the patients that are ctDNA positive or that convert to ctDNA positive in a randomized fashion.

is trying to answer that question, treating with atezolizumab, using ctDNA to treat those patients. The modern study here in the US is also asking that question, using ctDNA to decide whether you intensify the treatment or whether you do you really need the treatment, and really only treating the patients that are ctDNA positive or that convert to ctDNA positive in a randomized fashion.

is trying to answer that question, treating with atezolizumab, using ctDNA to treat those patients. The modern study here in the US is also asking that question, using ctDNA to decide whether you intensify the treatment or whether you do you really need the treatment, and really only treating the patients that are ctDNA positive or that convert to ctDNA positive in a randomized fashion.

So I love that. And the Tembola trial did that in a non-randomized fashion using ctDNA and seeing if they can treat the patients that are ctDNA positive or convert to positive with adjuvant atezolizumab and seeing if those patients did better. And the nice thing is that they showed that One of the things that was really interesting, I thought that they showed was that high risk.

So I love that. And the Tembola trial did that in a non-randomized fashion using ctDNA and seeing if they can treat the patients that are ctDNA positive or convert to positive with adjuvant atezolizumab and seeing if those patients did better. And the nice thing is that they showed that One of the things that was really interesting, I thought that they showed was that high risk.

So I love that. And the Tembola trial did that in a non-randomized fashion using ctDNA and seeing if they can treat the patients that are ctDNA positive or convert to positive with adjuvant atezolizumab and seeing if those patients did better. And the nice thing is that they showed that One of the things that was really interesting, I thought that they showed was that high risk.

So so we categorize patients into high risk and low risk patients. Right. And yes, the high risk patients had CT DNA, but not all of them did. And then there were some patients that were not high risk, you know, by our criteria. And they about half of them still had positive CT DNA. So, you know, we think we're good using clinical baseline characteristics in terms of how to make patient how to.

So so we categorize patients into high risk and low risk patients. Right. And yes, the high risk patients had CT DNA, but not all of them did. And then there were some patients that were not high risk, you know, by our criteria. And they about half of them still had positive CT DNA. So, you know, we think we're good using clinical baseline characteristics in terms of how to make patient how to.

So so we categorize patients into high risk and low risk patients. Right. And yes, the high risk patients had CT DNA, but not all of them did. And then there were some patients that were not high risk, you know, by our criteria. And they about half of them still had positive CT DNA. So, you know, we think we're good using clinical baseline characteristics in terms of how to make patient how to.

how to stratify patients into the highest risk. But we may not be capturing all the patients that are actually high risk and do need treatment in the adjuvant setting. So I really like that part of the Tembola trial and then following them and seeing they convert you know, how many of them converted with treatment, and then how did they do with the tezolizumab treatment.

how to stratify patients into the highest risk. But we may not be capturing all the patients that are actually high risk and do need treatment in the adjuvant setting. So I really like that part of the Tembola trial and then following them and seeing they convert you know, how many of them converted with treatment, and then how did they do with the tezolizumab treatment.

how to stratify patients into the highest risk. But we may not be capturing all the patients that are actually high risk and do need treatment in the adjuvant setting. So I really like that part of the Tembola trial and then following them and seeing they convert you know, how many of them converted with treatment, and then how did they do with the tezolizumab treatment.

So I think that this is a really important study, and more studies are going to be done that are actually randomized. So this kind of set the stage, and we have retrospective data also. So I think this kind of sets the stage for the importance of ctDNA within this perioperative study, and then what to do if you do have a positive ctDNA response. how to follow the patients, kind of what to expect.

So I think that this is a really important study, and more studies are going to be done that are actually randomized. So this kind of set the stage, and we have retrospective data also. So I think this kind of sets the stage for the importance of ctDNA within this perioperative study, and then what to do if you do have a positive ctDNA response. how to follow the patients, kind of what to expect.

So I think that this is a really important study, and more studies are going to be done that are actually randomized. So this kind of set the stage, and we have retrospective data also. So I think this kind of sets the stage for the importance of ctDNA within this perioperative study, and then what to do if you do have a positive ctDNA response. how to follow the patients, kind of what to expect.

I mean, this is all evolving right now as we speak. So I think it's really exciting to have a biomarker to work with.

I mean, this is all evolving right now as we speak. So I think it's really exciting to have a biomarker to work with.

I mean, this is all evolving right now as we speak. So I think it's really exciting to have a biomarker to work with.

That's a little much. We decreased that. And I liked how sensitive it was, really, of the ctDNA negative patients. Only two of the patients developed metastases. Now, of course, my hope would be that it would be zero and that it would be super sensitive and it would pick that up. And we saw that also.

That's a little much. We decreased that. And I liked how sensitive it was, really, of the ctDNA negative patients. Only two of the patients developed metastases. Now, of course, my hope would be that it would be zero and that it would be super sensitive and it would pick that up. And we saw that also.